96 2008 4 15 2 Ch in J C lin Tho rac Cardiovasc Surg, A p ril 2008,V o l. 15,No. 2 1 1 1 2 2 1 1 1 1 (1. ; 21, 650118) : (C IK) (N SCL C) g g g a N SCL C 50,, C IK, 25 ; 2 4 8, CD 3 + CD 4 + CD 4 + gcd 8 + N K T h1gt h2 C IK C IK 2, CD 3 + CD 4 + T N K CD 4 + gcd 8 + 22 ( IL 22) Χ( IN F2Χ) (P < 0. 01), 4, ; T h2 C IK 2, 4 C IK C IK 2 4 8 CD 3 + CD 4 + CD 4 + gcd 8 + N K IL 22 IN F2Χ 4 ( IL 24) 10 ( IL 210) [ (P < 0. 05), 4 CD 3 + 70. 2% 9. 1% vs. 46. 3% 5. 8% ; CD 4 + 40. 2% 7. 1% vs. 2219% 4. 5% ; CD 4 + gcd 8 + 1. 82 0. 43 vṡ 1. 09 0. 34; N K 15. 7% 5. 4% vs. 10. 5% 2. 5% ; IL 22 34. 8 11. 7 nggl vs. 19. 8 12. 1 nggl ; IN F2Χ63. 7 23. 3 nggl vs. 30. 8 10. 6 nggl ; IL 24 10. 2 8. 6 nggl vs. 25. 8 6. 3 nggl ; IL 210 10. 6 3. 4 nggl vs. 21. 4 8. 6 nggl ] C IK N SCL C : ; ; ; : R 655. 3: A : 100724848 (2008) 0220096205 Effect of Cytok ine- induced K iller Cells Imm unotherapy on Imm un ity Function of Non- small Cell L ung Cancer Patien ts af ter Operation Y E L ian2hua 1, H UA N G Y un2chao 1, ZH A O Guang 2qiang 1, W A N G X i2cai 2, ZH OU Y ong 2 chun 2, M A Q ian2li 1, L E I Y u2j ie 1, CH EN A n2ning 1, W A N G K un 1. (1. D ep artm ent of T horacic and Card iovascu lar S u rg ery, the T h ird A f f iliated H osp ital, K unm ing M ed ical Colleg e, T he Center of L ung Cancer R esearch of Y unnan P rov ince, K unm ing 650118, P. R. Ch ina; 2. T he Center of B iolog ical Imm unity T herapy, the T h ird A f f iliated H osp ital, K unm ing M ed ical Colleg e, K unm ing 650118, P. R. Ch ina) Corresp ond ing au thor: H UA N G Y un2chao, E 2m ail: H uangy ch2001@y ahoo. com. cn Abstract: Objective To investigate the effect of cytok ine2induced k iller (C IK ) cells imm uno therapy on imm unity function of non2sm all cell lung cancer (N SCL C) patients after operation. M ethods F ifty patients w ith h isto logical o r cyto logical diagno sis of N SCL C on g stage, g stage and g a stage of tum o r, nodes, m etastasis2 classification w ere random ly divided C IK cells therapy group and conventional therapy group, 25 cases each group. T he imm unity function of patients w ith N SCL C, including the levels of CD 3 +, CD 4 + T cells, ratio of CD 4 + gcd 8 +, natural k iller (N K) cells, and the levels of T h1gt h2 cytok ine w ere detected befo re treatm ent, and the 2nd, 4th, 8th w eek after treatm enṫ Results T he levels of CD 3 +, CD 4 + T cells, N K cells, ratio of CD 4 + gcd 8 +, interleuk in22 ( IL 22), interferon2χ( IN F2Χ) in C IK cells therapy group at the 2nd w eek after treatm ent w ere mo re h igher than tho se befo re treatm ent ( P < 0. 01), their levels reached the peak at 4th w eek, from then on, it began to decrease. M eanw h ile, the levels of T h2 of C IK cells therapy group began to decrease at the 2nd w eek after treatm ent, a low ebb at 4th w eek. A t the 2nd, 4th and 8th w eek, the levels of CD 3 +, CD 4 + T cells, ratio of CD 4 + gcd 8 +, N K cells, IL 2 2, IN F2Χ, interleuk in24 ( IL 24 ), interleuk in210 ( IL 210 ) of C IK cells therapy group com pared w ith tho se in conventional therapy group, there w ere statistical significance difference [ (P < 0. 05), at 4th w eek after treatm ent, : (2007C009Z) ; (KYCX200501) ; (06y113C) :, E2m ail: huangych2001@yahoo. com. cn
2008 4 15 2 Ch in J C lin Tho rac Cardiovasc Surg, A p ril 2008,V o l. 15,No. 2 97 CD 3 + 70. 2% 9. 1% vs. 46. 3% 5. 8% ; CD 4 + 40. 2% 7. 1% vs. 22. 9% 4. 5% ; CD 4 + gcd 8 + 1. 82 0. 43 vs. 1109 0. 34; N K 15. 7% 5. 4% vs. 10. 5% 2. 5% ; IL 22 34. 8 11. 7 nggl vs. 19. 8 12. 1 nggl ; IN F2Χ 63. 7 2313 nggl vs. 30. 8 10. 6 nggl ; IL 24 10. 2 8. 6 nggl vs. 25. 8 6. 3 nggl ; IL 210 10. 6 3. 4 nggl vs. 21. 4 8. 6 ngg L ]. Conclusion T he results indicate that C IK cells imm uno therapy can enhance the imm une function of N SCL C patients after operation. Key words: Cytok ine2induced k iller cell; N on2sm all cell lung cancer; Imm unity function; Cytok ine Foundation item: Emphasis P ro ject Suppo rted by Yunnan P rovince fo r A pp lication R esearch (2007C009Z); N ew Ideas Co lonia Fund of Kunm ing M edical Co llege (KYCX200501); T he Education Fund of Yunnan P rovince (06y113C),, [1, 2 ] (cytok ine2induced k iller, C IK) [3, 4 ] C IK ( non2sm all cell lung cancer,n SCL C), C IK, C IK N SCL C 1 1. 1 2006 1 6 N SCL C 50, 39, 11 ; 33 71 (48. 6 9. 4 ),, 50 N SCL C C IK, 25 (P > 0. 05), 1, 1( ) C IK 25 25 g 20g5 19g6 ( ) 47. 8 9. 5 48. 9 9. 2 11 13 14 12 14 14 8 9 3 2 TNM g 4 3 g 12 13 g a 9 9 1. 2 CS23000PLU S ( Bax ter ) Cou lter () ( BD )( Gibco ) CD 3 (monoclonal an tibody CD 3, M A bcd 3, R &D ) 2 ( IL 22),, Χ( IN F2Χ), 1. 3 1. 3. 1 4 (NVB ) + (DD P) (N P), NVB 25 30m ggm 2,, 1d 8d; DD P 25 30m ggm 2,, 1 3d; 4, 6 2 4% 750m l, 3, 1, 250m l, C IK, 2, (PBM C),, 5 10 5, IN F2Χ M A bcd 3 IL 22,, C IK 1. 6 10 9,,,, 3, IL 22 (3 10 6 U ) 20 % 150m l 600 m l, 3, 1, 3d 1. 3. 2 C IK C IK 2 4 8, 2 4 8, CD 3 + CD 4 + CD 4 + gcd 8 + (N K)
98 2008 4 15 2 Ch in J C lin Tho rac Cardiovasc Surg, A p ril 2008,V o l. 15,No. 2 T h1 ( IL 22 IN F2Χ) T h2 [ 24 ( IL 2 4) 210 ( IL 210) ] 1. 4 (X { s),, SPSS13. 0 2 2, 23 ; C IK 25, 48 2. 1 C IK C IK 2, CD 3 + CD 4 + T N K CD 4 + gcd 8 + (P < 0. 01),, 4 ;,, C IK 8, CD 3 + CD 4 + T N K CD 4 + gcd 8 +, (P < 0105) C IK C IK 2 4 8, CD 3 + CD 4 + CD 4 + g CD 8 + N K (P < 0105), 2 2. 2T h1gt h2 T h1gt h2 (P > 0. 05) C IK C IK IL 22 IN F2Χ, 4, 8 ; ( P < 0. 05) ; T h2 ( IL 24 IL 210) C IK 2, 4 ; (P < 0. 05), 3 2 (X { s) 2 4 8 CD 3 + (% ) 49. 6 8. 2 48. 1 8. 5 46. 3 5. 8 43. 9 7. 8 C IK 44. 8 4. 9 62. 1 8. 3 33 70. 2 9. 1 33 56. 3 7. 4 3 CD 4 + (% ) 23. 7 5. 4 22. 1 6. 9 22. 9 4. 5 19. 7 6. 3 C IK 22. 1 6. 7 30. 7 6. 5 33 40. 2 7. 1 33 29. 5 6. 2 3 CD 4 + gcd 8 + 1. 17 0. 24 1. 08 0. 27 1. 09 0. 34 1. 06 0. 28 C IK 1. 16 0. 24 1. 38 0. 31 33 1. 82 0. 43 33 1. 23 0. 32 3 N K (% ) 10. 4 2. 9 10. 9 2. 9 10. 5 2. 5 10. 3 2. 3 C IK 10. 9 3. 2 12. 6 3. 0 3 15. 7 5. 4 33 12. 1 2. 0 3 : 3 P < 0. 05, 33 P < 0. 01 3 T h1gt h2 (nggl, X { s) 2 4 8 IL 22 24. 7 10. 2 20. 5 10. 5 19. 8 12. 1 19. 3 9. 7 C IK 24. 5 10. 7 30. 9 12. 1 33 34. 8 11. 7 33 26. 3 7. 9 3 IN F2Χ 32. 4 11. 8 31. 9 8. 3 30. 8 10. 6 28. 5 13. 7 C IK 31. 8 12. 2 52. 3 20. 6 33 63. 7 23. 3 33 41. 3 14. 7 33 IL 24 23. 8 6. 5 26. 1 5. 3 25. 8 6. 3 28. 7 8. 6 C IK 23. 1 8. 3 16. 4 7. 9 33 10. 2 8. 6 33 18. 5 7. 5 33 IL 210 17. 6 7. 2 20. 1 6. 9 21. 4 8. 6 21. 7 7. 8 C IK 17. 9 5. 8 14. 2 4. 7 33 10. 6 3. 4 33 15. 4 5. 5 3 : 3 P < 0. 05, 33 P < 0. 01 3,,, N SCL C 3. 1 C IK C IK, IN F 2Χ IL 22 M A bcd 3, T N K (M HC ), CD 3 + CD 56 +,
2008 4 15 2 Ch in J C lin Tho rac Cardiovasc Surg, A p ril 2008,V o l. 15,No. 2 99 [4, 5 ] C IK,, C IK,,, ;, ; [3, 6 ] C IK :,,,, Fas2Fasl ; [2, 3 ], C IK 3. 2 C IK C IK,,, [3, 5 ], [7, 8 ],, C IK N SCL C, ; N P 2 C IK,,, C IK,,, 3. 3 C IK T,, [4, 9 ] : T, CD 4 + CD 4 + gcd 8 + T, ; C IK, N SCL C CD 3 + CD 4 + T N K CD 4 + gcd 8 + N SCL C C IK,, T,,, [7, 8 ], C IK, : C IK 2, 4, 8 N SCL C C IK 1, 1. 6 10 9, 8 1 8,, 3. 4 C IK T h1gt h2,, T T h1 T h2, T h1, IL 22 TN F2Α IN F2Χ; T h2, IL 24 IL 25 IL 210,, T h1, T h2,, [7, 8, 10 ], T h1 T h2 N SCL C T h1gt h2, C IK N SCL C T h1, T h2, C IK T h1 T h2 T h1gt h2, : C IK N SCL C T T h1gt h2,, 1 Patel S, M ehta2d am ani A, Shu H, et al. A n analysis of variability in the m anufacturing of dexo som es: imp lications fo r developm ent of an auto logous therapy. B io techno l B ioeng, 2005, 92 (2) : 2382249. 2,,,. L unx mrna., 2007, 14 (3) : 1842 187. 3 J iang J, Xu N, W u C, et al. T reatm ent of advanced gastric cancer by chemo therapy com bined w ith auto logous cytokine2 induced killer cells. A nticancer Res, 2006, 26 (3B) : 223722242. 4,,,. C IK., 2006, 25 (11) : 132921333. 5 Hongeng S, Petvises S, W o rapongpaiboon S, et al. Generation of CD 3 + CD 56 + cytok ine induced k iller cells and their in vitro
100 2008 4 15 2 Ch in J C lin Tho rac Cardiovasc Surg, A p ril 2008,V o l. 15,No. 2 cyto toxicity against pediatric cancer cells. Int J H em ato l, 2003, 77 (2) : 1752179. 6,,,. C IK., 2005, 12 (1) : 35240. 7 M ndez R, Ruiz2Cabello F, Rodr guez T, et al. Identification of different tumo r escape m echanism s in several m etastases from a m elanom a patient undergo ing imm uno therapy. Imm uno ther, 2007, 56 (1) : 88294. Cancer Imm uno l 8,,. T., 2005, 12 (3) : 1692172. 9 ShiM, Zhang B, Tang ZR, et al. A uto logous cytokine2induced killer cell therapy in clinical trial phaseg is safe in patients w ith p rim ary hepatocellular carcinom a. W o rld J Gastroentero l, 2004, 10 (8) : 114621151. 10 Ren X, Yu J, L iu H, et al. Th1 bias in PBM C induced by m ulticycles of auto2c IKs infusion in m alignant so lid tumo r patientṡ Cancer B io ther Radiopharm, 2006, 21 (1) : 22223. : 2007208214 : 2007210225 (, 010059) : R 655. 5: D : 100724848 (2008) 0220100201 1, 15 2d : X CT :, ( 1), :, 1 CT :, 1 2,,, 4d,,,, 11d CT :, 1 9,,,,, X CT,,, [1 ],, 1 2 ;,, 1cm, [2 ],,,, 1CT 2, 24 1, 1d :,, X CT :,,, 1 Chiang KH, Chou A S. Im ages in clinical m edicine. Pneumom ediastinum. N Engl J M ed, 2006, 354 (11) : 1177. 2 A bo lnik I, Lo sso s IS, B reuer R. Spontaneous pneumo2 m ediastinum: A repo rt of 25 cases. Chest, 1991, 100 (1) : 93295. : 2007206204 : 2007208208